February 14th 2025
Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.
UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.
Laurence Albigès, MD, PhD discusses final OS data and biomarker analyses with cabozantinib plus nivolumab and ipilimumab in intermediate- or poor-risk RCC.
Enfortumab vedotin, both as monotherapy and in combination with pembrolizumab, demonstrated clinical activity in patients with UTUC lesions.
Consistent DFS benefit was observed with adjuvant nivolumab vs placebo in all patients with muscle-invasive bladder cancer enrolled in CheckMate-274.
Enfortumab vedotin significantly improved outcomes for patients with unresectable or metastatic urothelial carcinoma, according to real-world data.
Responses were similar among patients with estrogen patches and ARPIs compared to aLHRH and ARPIs in metastatic prostate cancer.
First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.
Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.
Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.
February 13th 2025
The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.
Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.
A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.
G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.
Adding Lu-PSMA-617 to enzalutamide significantly improved overall survival and quality of life in metastatic castration-resistant prostate cancer.
Talazoparib plus enzalutamide demonstrates improved overall survival in metastatic castration-resistant prostate cancer.
February 12th 2025
Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.
February 5th 2024
Tinengotinib elicited responses with a manageable safety profile in heavily pretreated patients with metastatic castration-resistant prostate cancer.
January 28th 2024
Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.
January 27th 2024
Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.
